Tedizolid
Indications: - Methicillin resistant Staphylococcus aureus - Vancomycin resistant Staphylococcus aureus - Vancomycin resistant Enterococcus Source: EML workbook import

Browse procurement-ready healthcare products from trusted vendors across the Afya Chain marketplace.
Indications: - Methicillin resistant Staphylococcus aureus - Vancomycin resistant Staphylococcus aureus - Vancomycin resistant Enterococcus Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule Indications: - Unspecified appropriateness of dosing or administration without injury or harm Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL) Indications: - Hypokalaemia Source: EML workbook import
Formulations: - Parenteral > General injections > IV: injectable solution Indications: - Other specified disorders of fluid, electrolyte or acid-base balance - Hypovolaemic shock Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 5% isotonic; 10% hypertonic Parenteral > General injections > IV: 50% hypertonic Indications: - Other specified disorders of fluid, electrolyte or acid-base balance - Hypoglycaemia without associated diabetes Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L) Indications: - Other specified disorders of fluid, electrolyte or acid-base balance Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L) Indications: - Other specified disorders of fluid, electrolyte or acid-base balance Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L) Indications: - Acidosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg; 600 mg Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule Oral > Solid > tablet: 400 mg; 600 mg Oral > Other: 600 mg Oral > Solid > tablet: 400 mg Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Osteosarcoma of bone and articular cartilage of other specified sites - Burkitt lymphoma including Burkitt leukaemia - Ewing sarcoma of bone and articular cartilage of unspecified sites - Malignant neoplasms of kidney, except renal pelvis - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Rhabdomyosarcoma primary site Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution Indications: - Tumour lysis syndrome Source: EML workbook import
Indications: - Other specified malignant neoplasms of bronchus or lung Source: EML workbook import
Formulations: - Oral > Solid: 10 mg capsule Indications: - Acute myeloid leukaemia with recurrent genetic abnormalities Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.